ERBB2 and breast cancer: Previous studies have documented the gain in PIK3CA CN in patients with BC, but reports on its frequency have been conflicting, ranging from 1.4%13 to as high as 72%14, with two of the most recent studies reporting frequencies of 9%9 and 17.4%15 in HR + and luminal/HER2−, respectively.